2-(3-pyridinyl)-4-thiophen-2-ylthiazole, also known as **thiazole derivative** or **thiazole analog**, is a chemical compound with a unique structure containing a thiazole ring fused to a pyridine ring and a thiophene ring.
**Importance in Research:**
This compound is of significant interest to researchers due to its potential applications in various fields:
* **Pharmacology:**
* **Anti-cancer activity:** Thiazole derivatives have shown promising anti-cancer activity against various cancer cell lines, including leukemia, breast, and colon cancer. They can potentially interfere with cell proliferation and induce apoptosis (programmed cell death).
* **Anti-inflammatory activity:** Some thiazole derivatives exhibit anti-inflammatory properties, which could be beneficial in treating inflammatory diseases like arthritis.
* **Antimicrobial activity:** Thiazoles have been explored for their antibacterial and antifungal properties, potentially contributing to the development of new antibiotics and antifungals.
* **Neuroprotective activity:** Some thiazole compounds have shown potential in protecting neurons from damage caused by oxidative stress and neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Materials Science:**
* **Organic electronics:** Thiazoles and their derivatives can act as building blocks for organic semiconductors and photovoltaic materials due to their unique electronic properties.
* **Agriculture:**
* **Herbicides and pesticides:** Thiazoles have been investigated for their potential use as herbicides and pesticides, offering alternatives to conventional chemical agents.
**Further Research:**
Ongoing research focuses on:
* **Synthesis and characterization:** Developing efficient and environmentally friendly methods to synthesize these compounds and understand their structural properties.
* **Biological activity evaluation:** Investigating the mechanisms of action and efficacy of thiazoles against various diseases.
* **Structure-activity relationship (SAR) studies:** Exploring how modifications to the thiazole molecule affect its biological activity to design more potent and specific compounds.
* **Clinical trials:** Testing the safety and efficacy of promising thiazole derivatives in human subjects.
Overall, 2-(3-pyridinyl)-4-thiophen-2-ylthiazole and its analogs represent a valuable class of compounds with potential applications in a variety of fields. Further research is crucial to unlocking their full potential and translating these findings into practical applications.
ID Source | ID |
---|---|
PubMed CID | 2348844 |
CHEMBL ID | 1572708 |
CHEBI ID | 121220 |
Synonym |
---|
ENAMINE_002702 |
MLS000098137 |
smr000061212 |
IDI1_007049 |
CHEBI:121220 |
HMS1401K18 |
2-pyridin-3-yl-4-thiophen-2-yl-1,3-thiazole |
HMS2153E11 |
HMS3314K02 |
CHEMBL1572708 |
Q27209751 |
2-(3-pyridinyl)-4-thiophen-2-ylthiazole |
Z48847419 |
AKOS034400990 |
Class | Description |
---|---|
thiazoles | An azole in which the five-membered heterocyclic aromatic skeleton contains a N atom and one S atom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 25.1189 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 25.1189 | 0.0251 | 20.2376 | 39.8107 | AID893 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 35.4813 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 39.8107 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 26.8545 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
Nrf2 | Homo sapiens (human) | Potency | 11.2202 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 12.5893 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
Smad3 | Homo sapiens (human) | Potency | 6.3096 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
hypothetical protein, conserved | Trypanosoma brucei | Potency | 3.9811 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 12.5893 | 0.2818 | 9.7212 | 35.4813 | AID2326 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 50.1187 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 14.5810 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 7.3078 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0398 | 16.7842 | 39.8107 | AID995 |
snurportin-1 | Homo sapiens (human) | Potency | 7.3078 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 7.3078 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 4 (66.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.35) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |